PHILADELPHIA, PA — FORE Biotherapeutics has announced that its plixorafenib abstract has been selected for poster presentation at the highly anticipated 2025 American Society of Clinical Oncology Annual Meeting (ASCO), scheduled from May 30 to June 3 in Chicago.
The presentation will focus on the FORTE Master Protocol, a global Phase 2 study evaluating plixorafenib across multiple BRAF-driven cancers. The study includes four sub-protocols, exploring the efficacy of plixorafenib monotherapy for patients with BRAF V600 recurrent primary central nervous system (CNS) tumors, rare BRAF V600 mutated solid tumors, and solid tumors with BRAF fusions.
Dr. Karisa Schreck, M.D., Ph.D., of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will present a poster detailing the trial’s innovative design and its potential implications for precision oncology.
Poster Presentation Details:
- Title: FORTE: A Phase 2 Master Protocol Assessing Plixorafenib for BRAF-Altered Cancers
- Session: Central Nervous System Tumors
- Date and Time: Saturday, May 31, 2025; 9:00 a.m. – 12:00 p.m. CT
- Presenter: Karisa Schreck, M.D., Ph.D., Johns Hopkins University
- Abstract Number: TPS2091
The FORTE Master Protocol underscores FORE Biotherapeutics’ commitment to addressing unmet needs in BRAF-altered cancers through advanced clinical trials targeting distinct patient populations. With this presentation, the company aims to showcase the promise of plixorafenib in tackling rare and recurrent cancers and advancing personalized treatment options.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.